UBS AM’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,360,524
| Closed | -$48.2M | – | 2721 |
|
|
2025
Q1 | $48.2M | Buy |
4,360,524
+2,983,368
| +217% | +$33M | 0.01% | 697 |
|
|
2024
Q4 | $14.7M | Buy |
1,377,156
+36,084
| +3% | +$384K | ﹤0.01% | 1080 |
|
|
2024
Q3 | $17M | Buy |
1,341,072
+21,072
| +2% | +$268K | ﹤0.01% | 1007 |
|
|
2024
Q2 | $22.1M | Buy |
+1,320,000
| New | +$22.1M | 0.01% | 831 |
|
|
2022
Q2 | – | Sell |
-22,400
| Closed | -$195K | – | 2774 |
|
|
2022
Q1 | $195K | Hold |
22,400
| – | – | ﹤0.01% | 2685 |
|
|
2021
Q4 | $213K | Hold |
22,400
| – | – | ﹤0.01% | 2753 |
|
|
2021
Q3 | $377K | Hold |
22,400
| – | – | ﹤0.01% | 2579 |
|
|
2021
Q2 | $342K | Hold |
22,400
| – | – | ﹤0.01% | 2624 |
|
|
2021
Q1 | $436K | Hold |
22,400
| – | – | ﹤0.01% | 2429 |
|
|
2020
Q4 | $404K | Hold |
22,400
| – | – | ﹤0.01% | 2358 |
|
|
2020
Q3 | $432K | Buy |
22,400
+3,299
| +17% | +$63.6K | ﹤0.01% | 2198 |
|
|
2020
Q2 | $499K | Sell |
19,101
-2,700
| -12% | -$70.5K | ﹤0.01% | 2131 |
|
|
2020
Q1 | $389K | Buy |
21,801
+5,400
| +33% | +$96.3K | ﹤0.01% | 2069 |
|
|
2019
Q4 | $547K | Buy |
+16,401
| New | +$547K | ﹤0.01% | 2197 |
|
|
2019
Q3 | – | Sell |
-6,100
| Closed | -$219K | – | 2903 |
|
|
2019
Q2 | $219K | Hold |
6,100
| – | – | ﹤0.01% | 2514 |
|
|
2019
Q1 | $225K | Buy |
+6,100
| New | +$225K | ﹤0.01% | 2415 |
|